US 11,730,711 B2
Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels
Stephen Kirnon, San Ramon, CA (US); Eric Freedland, Marblehead, MA (US); and Rajagopal V. Sekhar, Missouri City, TX (US)
Assigned to Baylor College of Medicine, Houston, TX (US); and Societe de Produits Nestle S.A., Vevey (CH)
Filed by SOCIÉTÉ DES PRODUITS NESTLÉ S.A., Vevey (CH); and BAYLOR COLLEGE OF MEDICINE, Houston, TX (US)
Filed on Feb. 12, 2021, as Appl. No. 17/175,111.
Application 17/175,111 is a continuation of application No. 15/577,422, granted, now 10,952,982, previously published as PCT/US2016/034078, filed on May 25, 2016.
Claims priority of provisional application 62/167,433, filed on May 28, 2015.
Prior Publication US 2021/0244696 A1, Aug. 12, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/198 (2006.01); A61K 38/05 (2006.01); A61K 31/167 (2006.01); A61K 31/223 (2006.01); A61K 31/341 (2006.01); A61K 38/21 (2006.01); A61K 31/683 (2006.01); A61K 31/27 (2006.01); A61K 45/06 (2006.01); A61K 31/381 (2006.01); A61K 31/205 (2006.01); A23K 20/142 (2016.01); A23K 50/50 (2016.01); A61P 21/00 (2006.01); A61P 39/00 (2006.01); A61P 31/18 (2006.01); A61P 29/00 (2006.01); A61K 38/02 (2006.01)
CPC A61K 31/198 (2013.01) [A23K 20/142 (2016.05); A23K 50/50 (2016.05); A61K 31/167 (2013.01); A61K 31/205 (2013.01); A61K 31/223 (2013.01); A61K 31/27 (2013.01); A61K 31/341 (2013.01); A61K 31/381 (2013.01); A61K 31/683 (2013.01); A61K 38/02 (2013.01); A61K 38/05 (2013.01); A61K 38/21 (2013.01); A61K 45/06 (2013.01); A61P 21/00 (2018.01); A61P 29/00 (2018.01); A61P 31/18 (2018.01); A61P 39/00 (2018.01)] 9 Claims
 
1. A method of treating an individual for a medical condition or physical state, the method comprising providing to the individual an effective amount of a composition comprising glycine or a functional derivative thereof and N-acetylcysteine, wherein the medical condition or physical state is selected from the group consisting of:
muscle loss;
deleterious effects of weightlessness;
osteoporosis;
polycystic ovary syndrome (PCOS);
coronary artery disease;
myocardial damage after stress;
insufficient immunity following vaccination;
ototoxicity;
dizziness; and
a combination thereof.